PDF
File
Kurs
+0,73%
Likviditet
152 MSEK
Kalender
| Tid* | ||
| 2025-04-22 | N/A | Årsstämma |
| 2025-01-28 | 08:00 | Bokslutskommuniké 2024 |
| 2024-10-18 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-18 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-23 | - | X-dag ordinarie utdelning GETI B 4.40 SEK |
| 2024-04-22 | - | Årsstämma |
| 2024-04-22 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-01 | - | Bokslutskommuniké 2023 |
| 2023-10-23 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | X-dag ordinarie utdelning GETI B 4.25 SEK |
| 2023-04-26 | - | Årsstämma |
| 2023-04-26 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-01 | - | Bokslutskommuniké 2022 |
| 2022-10-19 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-19 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-27 | - | X-dag ordinarie utdelning GETI B 4.00 SEK |
| 2022-04-26 | - | Årsstämma |
| 2022-04-26 | - | Kvartalsrapport 2022-Q1 |
| 2022-01-28 | - | Bokslutskommuniké 2021 |
| 2021-10-20 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-16 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-21 | - | X-dag ordinarie utdelning GETI B 3.00 SEK |
| 2021-04-20 | - | Årsstämma |
| 2021-04-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-01-28 | - | Bokslutskommuniké 2020 |
| 2020-10-16 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-29 | - | X-dag ordinarie utdelning GETI B 1.50 SEK |
| 2020-06-26 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-01-30 | - | Bokslutskommuniké 2019 |
| 2019-10-18 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-17 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-24 | - | X-dag ordinarie utdelning GETI B 1.00 SEK |
| 2019-04-23 | - | Årsstämma |
| 2019-04-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-01-30 | - | Bokslutskommuniké 2018 |
| 2018-10-18 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-27 | - | X-dag ordinarie utdelning GETI B 1.50 SEK |
| 2018-04-26 | - | Årsstämma |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-29 | - | Bokslutskommuniké 2017 |
| 2017-10-18 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-17 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-30 | - | X-dag ordinarie utdelning GETI B 2.00 SEK |
| 2017-03-29 | - | Årsstämma |
| 2017-01-26 | - | Bokslutskommuniké 2016 |
| 2016-10-18 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-14 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-22 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-31 | - | X-dag ordinarie utdelning |
| 2016-03-30 | - | Årsstämma |
| 2016-01-28 | - | Bokslutskommuniké 2015 |
| 2015-10-15 | - | Kvartalsrapport 2015-Q3 |
| 2015-09-02 | - | Extra Bolagsstämma 2015 |
| 2015-07-15 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-20 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-26 | - | X-dag ordinarie utdelning GETI B 2.80 SEK |
| 2015-03-25 | - | Årsstämma |
| 2015-01-28 | - | Bokslutskommuniké 2014 |
| 2014-10-16 | - | Kvartalsrapport 2014-Q3 |
| 2014-10-16 | - | Analytiker möte 2014 |
| 2014-07-15 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-16 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning GETI B 4.15 SEK |
| 2014-03-20 | - | Årsstämma |
| 2014-01-28 | - | Bokslutskommuniké 2013 |
| 2013-10-15 | - | Kvartalsrapport 2013-Q3 |
| 2013-10-15 | - | Analytiker möte 2013 |
| 2013-10-15 | - | 15-7 2013 |
| 2013-07-11 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-17 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-22 | - | X-dag ordinarie utdelning GETI B 4.15 SEK |
| 2013-03-21 | - | Årsstämma |
| 2013-02-08 | - | Kapitalmarknadsdag 2013 |
| 2013-01-25 | - | Bokslutskommuniké 2012 |
| 2012-10-17 | - | Kvartalsrapport 2012-Q3 |
| 2012-10-17 | - | Analytiker möte 2012 |
| 2012-07-11 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-19 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-29 | - | X-dag ordinarie utdelning GETI B 3.75 SEK |
| 2012-03-28 | - | Årsstämma |
| 2012-01-26 | - | Bokslutskommuniké 2011 |
| 2011-10-20 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-11 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | X-dag ordinarie utdelning GETI B 3.25 SEK |
| 2011-04-27 | - | Årsstämma |
| 2011-04-27 | - | Kvartalsrapport 2011-Q1 |
| 2011-01-28 | - | Kapitalmarknadsdag 2011 |
| 2011-01-26 | - | Bokslutskommuniké 2010 |
| 2010-10-19 | - | Kvartalsrapport 2010-Q3 |
| 2010-04-23 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
| 2010-04-22 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
| 2010-04-21 | - | Årsstämma |
| 2010-04-21 | - | Kvartalsrapport 2010-Q1 |
| 2010-01-26 | - | Bokslutskommuniké 2009 |
| 2009-07-13 | - | Kvartalsrapport 2009-Q2 |
| 2009-05-06 | - | Kvartalsrapport 2009-Q3 |
| 2009-04-22 | - | X-dag ordinarie utdelning GETI B 2.40 SEK |
| 2009-04-21 | - | Årsstämma |
| 2009-04-21 | - | Kvartalsrapport 2009-Q1 |
| 2008-04-18 | - | X-dag ordinarie utdelning GETI B 2.40 SEK |
| 2007-04-20 | - | X-dag ordinarie utdelning GETI B 2.20 SEK |
| 2006-04-21 | - | X-dag ordinarie utdelning GETI B 2.00 SEK |
| 2005-04-20 | - | X-dag ordinarie utdelning GETI B 1.65 SEK |
| 2004-04-22 | - | X-dag ordinarie utdelning GETI B 1.35 SEK |
| 2003-11-25 | - | Split GETI B 1:4 |
| 2003-04-24 | - | X-dag ordinarie utdelning GETI B 4.25 SEK |
| 2002-04-19 | - | X-dag ordinarie utdelning GETI B 3.75 SEK |
| 2001-04-24 | - | X-dag ordinarie utdelning GETI B 3.50 SEK |
| 2000-04-28 | - | X-dag ordinarie utdelning GETI B 3.50 SEK |
| 1999-04-22 | - | X-dag ordinarie utdelning GETI B 3.25 SEK |
| 1998-04-24 | - | X-dag ordinarie utdelning GETI B 2.75 SEK |
| 1997-04-30 | - | X-dag ordinarie utdelning GETI B 2.50 SEK |
| 1996-04-19 | - | X-dag ordinarie utdelning GETI B 6.00 SEK |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Today, Getinge announces the U.S. Food and Drug Administration's (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company's endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, the newcomer is expected to offer enhanced procedural efficiency in healthcare from the upcoming launch.
[image]
Receiving the FDA 510(k) clearance for Vasoview Hemopro 3 marks a significant milestone for Getinge and underscores the effort to comply with the highest safety and effectiveness standards, emphasizing the medtech company's commitment to advancing medtech.
"EVH is a therapy significantly helping patients towards faster recovery by minimizing surgical trauma and reducing post-operative pain. By offering solutions together with extensive training, we aim to continue help facilitating the widespread adoption of this essential therapy. The new generation of Vasoview - Hemopro 3 - symbolizes our dedication to elevating healthcare standards together with our customers," says Elin Frostehav, President Acute Care Therapies at Getinge.
The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements that enhance harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable.
Getinge is preparing for the product launch of Vasoview Hemopro 3 to occur in the US during the third quarter of 2024, while registration in additional key markets is underway.
Investor Relations:
Lars Mattsson, Head of Investor Relations
Phone: +46 10 335 0043
Email: lars.mattsson@getinge.com
Media contact:
Caroline Örmgård, Head of Public & Media Relations
Phone: +46 10 335 0041
Email: caroline.ormgard@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.